No benefit has been seen with two investigational drugs targeting amyloid beta in a major study aimed at preventing cognitive loss in the early stages of dominantly inherited Alzheimer’s disease. Initial results from the Dominantly Inherited Alzheimer Network-Trials Unit (DIAN-TU) that evaluated solanezumab, made by Eli Lilly and gantenerumab, made by Roche/Genentech, showed that the treatment ...
No benefit seen with two amyloid-targeting drugs in Alzheimers
By Michael Woodhead
11 Feb 2020